NCT06312566View on ClinicalTrials.gov

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions
Healthy Study Participants
Interventions
DRUG

brivaracetam (BRV) tablet

Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.

DRUG

brivaracetam (BRV) dry syrup

Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.

Trial Locations (1)

Unknown

EP0231 1, Sumida-ku

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT06312566 - A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants | Biotech Hunter | Biotech Hunter